Turning Point Therapeutics (TPTX) Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors. Garry Nicholson, who is currently the interim chair, will remain on the board.

Mr. Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career, which includes driving growth and innovation during 15 years at Celgene until its $74-billion acquisition by Bristol Myers Squibb in 2019.

President and CEO Athena Countouriotis, M.D., said: “Mark’s background, knowledge and experience align perfectly with our focus in oncology, the stage of our clinical assets and our aspirations for continued growth. On behalf of the entire board, we look forward to having Mark’s leadership as we focus on the advancement of our clinical stage drug candidates, build a pipeline for the future and move our lead asset closer to registration.”

Mr. Alles brings deep operational, financial, business development and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S. based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees. Prior to being named chair in 2018 and CEO in 2016, Mr. Alles served as Celgene president and chief operating officer, executive vice president and Global Head of Hematology & Oncology and chief commercial officer. Before joining Celgene in 2004, he was vice president of the U.S. Oncology business unit at Aventis Pharmaceuticals where he also served in other senior management roles during an 11-year period. He began his career in the biopharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson.

“This is an exciting time to join the Turning Point board, as the company plans for potential registration and commercialization of repotrectinib, advances a growing pipeline and makes investments to build upon the strong foundation it has established over the past two years since the IPO,” said Mr. Alles. “I look forward to working closely with such a distinguished board and management team.”

Mr. Alles is a member of the board of directors for Antengene Corporation and Syros Pharmaceuticals. He is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Biotechnology Innovation Organization (BIO).

You May Also Be Interested In

• Volato (SOAR) Announces Board Changes
• CoStar Group (CSGP) PT Raised to $107 at Needham
• Marsh McLennan Agency (MMC) to acquire Fisher Brown Bottrell Insurance, Inc.